Oscar Health (OSCR) presents a high-risk investment opportunity following its recent turnaround to profitability under CEO Mark Bertolini. While demonstrating strong revenue growth (42.2% YoY), improved operational efficiency, and positive cash flow, the insurtech faces existential regulatory risks tied to Affordable Care Act subsidies and policy stability. Despite its innovative technology platform and 2 million members, analyst downgrades, significant insider selling, fierce competition from insurance giants, and extreme stock volatility (Beta 1.90) create "asymmetric downside risk." The stock is suitable only for aggressive, long-term investors tolerant of policy-driven volatility, while conservative investors should avoid due to uncontrollable external threats.